For the Quarter Ending September 2025
North America
• In USA, the Glucosamine Price Index fell by 2.13% quarter-over-quarter, driven by cautious downstream procurement.
• The average Glucosamine price for the quarter was approximately USD 7808.33/MT, reported by export assessments.
• Steady exports and balanced inventories supported Glucosamine Spot Price stability despite procurement from downstream formulators.
• Short-term Glucosamine Price Forecast indicates gradual strengthening as seasonal restocking improves demand without supply disruptions.
• Stable raw material availability kept Glucosamine Production Cost Trend subdued, limiting upward pressure on offers.
• Inventory drawdowns and seasonal demand supported Glucosamine Demand Outlook heading into early fourth quarter momentum.
• Export enquiries rose ahead of winter production, reinforcing the Glucosamine Price Index trajectory toward gains.
• Major producers reported uninterrupted operations, keeping supply consistent and validating Glucosamine Spot Price resilience levels.
Why did the price of Glucosamine change in September 2025 in North America?
• Seasonal restocking increased procurement urgency, tightening available inventories and supporting upward price momentum in September.
• Uninterrupted production and stable feedstock supplies prevented cost shocks, keeping Glucosamine availability steady throughout September.
• Muted international buying during quarter reduced export volumes, exerting downward pressure on Glucosamine Price Index.
APAC
• In China, the Glucosamine Price Index fell by 11.33% quarter-over-quarter, driven by subdued export demand.
• The average Glucosamine price for the quarter was approximately USD 4723.33/MT, reflecting weak buyer restocking activity.
• Glucosamine Spot Price softened as suppliers reduced offers to clear elevated export inventories amid muted uptake.
• Glucosamine Price Forecast suggests modest firming into Q4 if seasonal replenishment sustains and inventories normalize.
• Glucosamine Production Cost Trend remained benign due to stable feedstock and energy benchmarks limiting upward pressure.
• Glucosamine Demand Outlook improved late September with formulators replenishing for winter production and promotional cycles.
• Glucosamine Price Index volatility reflected longer bearish pressures abating as export contracts and e-commerce sales firmed.
• Major Chinese producers maintained stable operations, supplying consistent volumes despite softer order flows and elevated stocks.
Why did the price of Glucosamine change in September 2025 in APAC?
• Elevated export inventories pressured offers as suppliers cut prices to maintain throughput and reduce stock.
• Stable feedstock and energy costs kept Glucosamine Production Cost Trend flat, removing upward cost-push support.
• Seasonal restocking and stronger formulators' procurement in September tightened spot availability, prompting modest price recovery.
Europe
• In Europe, the Glucosamine Price Index fell by ~8.5% quarter-over-quarter, pressured by softer export enquiries and ample imported volumes.
• The average Glucosamine price for the quarter was approximately USD 5,000.00/MT (conservative estimate due to limited consolidated transaction data).
• Glucosamine Spot Price softened as distributors and online retailers delayed restocking and cleared higher-than-normal inventories.
• Glucosamine Price Forecast suggests modest firming into Q4 if winter promotional buying and pharmaceutical/OTC replenishment pick up.
• Glucosamine Production Cost Trend remained muted with stable feedstock and moderate energy costs, limiting upward pressure on offers.
• Glucosamine Demand Outlook is cautious but shows pockets of improvement from supplement formulators preparing for seasonal demand.
• Glucosamine Price Index volatility reflected cross-border import flows, currency (EUR/USD) moves, and uneven purchasing across EU markets.
• European packers and distributors maintained steady operations, supplying volumes from inventories which contained sharp price moves.
Why did the price of Glucosamine change in September 2025 in Europe?
• Elevated inventories and weaker immediate procurement reduced distributor buying urgency, driving spot offers lower.
• Stable feedstock and energy costs kept production-cost pressure limited, so price changes were demand-led rather than cost-driven.
• Improved seasonal/formulator restocking late in the quarter tightened prompt availability slightly, supporting modest stabilization.
For the Quarter Ending June 2025
North America
• The Glucosamine Spot Price in the U.S. export market (FOB New Jersey) displayed a mild downtrend through Q2 2025 and closed at USD 7,560/MT in the fourth week of June. The price trend marked a 0.40% decline which was influenced by persistent weak demand both domestically and internationally.
• The Glucosamine Price Index recorded mixed movements through Q2—starting with a 1.04% decline in April then showing a 0.61% increase in mid-May and reverting to softness again in June. These modest fluctuations reflect cautious procurement amid stable availability.
• Why did the price change in July 2025?
In July, the price slightly declined further due to continued cautious buying from overseas pharmaceutical buyers with abundant inventories that left no room for speculative upticks.
• The Glucosamine Production Cost Trend remained stable across U.S. facilities during Q2 with no reported supply disruptions. Manufacturing units continued running at full capacity which was supported by consistent raw material access and efficient plant operations.
• Inventory drawdowns in early Q2 were slow, as many buyers utilized pre-stocked materials from Q1. This limited fresh procurement and kept the pricing environment competitive.
• The Glucosamine Demand Outlook remained neutral to weak. While routine purchases by pharmaceutical and nutraceutical players continued, there was no significant spike to stimulate a price rebound.
• Competitive East Asian imports—particularly from China—exerted price pressure in the U.S. market. Tariff-related uncertainties also made importers more price-sensitive.
• Freight and port operations across New Jersey and East Coast hubs remained efficient, with no logistical disruptions reported throughout the quarter.
• U.S. exporters adopted strategic pricing moderation to preserve market share against competing global suppliers, especially with lower cost offers arriving from Asia.
Asia Pacific
• The Glucosamine Spot Price in China (FOB Qingdao) showed a mixed Q2 trend, peaking in the first week of June with a 1.28% rise and retreating by 0.93% to USD 5,350/MT in the fourth week due to oversupply.
• The Glucosamine Price Index for Q2 in Asia Pacific reflected price firmness in May and early June, before slipping late in the quarter under elevated inventories and routine but unremarkable demand.
• Why did the price change in July 2025?
The price in July continued to soften slightly due to carryover inventories, cautious procurement behaviour among Southeast Asian buyers, and efforts by Chinese suppliers to clear stock ahead of Q3 cycles.
• The Glucosamine Production Cost Trend stayed relatively steady throughout Q2 in China, with full operational capacity and no raw material bottlenecks. Cost management was supported by stable chitin feedstock availability.
• Downstream demand, especially from the nutraceutical and pharmaceutical sectors, stayed consistent, yet lacked the scale to drive bullish price movement.
• The Glucosamine Demand Outlook across the Asia Pacific region remained stable but plateaued, with joint health supplement demand strong, yet incremental growth limited.
• Inventory turnover was healthy through early June, but later weeks saw some saturation, leading to price corrections as suppliers aimed to stimulate restocking.
• Export channels remained uninterrupted, and Qingdao port operations flowed seamlessly, ensuring no logistical friction for international buyers.
• Forward contracts from South Korea, Japan, and Southeast Asia supported stability in early Q2, but by late June, new inquiries had slowed, mirroring cautious end-user sentiment.
Europe
• The Glucosamine Spot Price across major European ports (e.g., Rotterdam and Hamburg) likely mirrored global trends in Q2 2025, beginning with mild softness in April, moving into neutral territory by May, and weakening slightly by late June due to elevated inventories.
• The Glucosamine Price Index in Europe likely followed a narrow range trend during the quarter, impacted by surplus stocks, modest procurement cycles, and competition from lower-cost Asian imports.
• Why did the price change in July 2025?
Prices in July dipped marginally due to muted demand from the supplement industry and sustained inflow of competitively priced Asian cargoes. Buyers continued to rely on pre-booked inventory.
• The Glucosamine Production Cost Trend remained neutral in Europe, with low domestic production activity and a high dependency on imports. Processing and distribution costs remained stable due to efficient intra-EU logistics.
• European buyers showed preference for spot purchases rather than long-term contracts during Q2, further indicating caution and tight inventory management.
• The Glucosamine Demand Outlook in Europe remained steady yet unspectacular, with regular consumption in dietary supplement formulations and pharma-grade Glucosamine demand holding firm.
• Import flows from China and India fulfilled most regional needs, with no major disruptions in customs or cargo handling reported.
• Demand from Germany, France, and the UK remained relatively stable, though price-sensitive buyers delayed restocking in June awaiting potential Q3 corrections.
• Overall market sentiment across Europe reflected a cautious outlook, with inventory-led procurement strategies, stable cost structures, and subdued momentum in new order placements.
For the Quarter Ending March 2025
North America
In the first quarter of 2025, the average price of Glucosamine in the North American market increased by 0.96% from concluding quarter of 2024. This moderate rise was largely supported by steady procurement activity from pharmaceutical and nutraceutical companies. The demand for joint health supplements and wellness products remained consistent during the colder months of January and February. The consumers relied on Glucosamine supplements and focused more on immunity and joint care in winter.
The seasonal shift from winter to early spring also influenced purchasing trends and resulted in buyers ensuring a stable inventory level to avoid supply disruptions. Additionally, tariff measures introduced during the quarter on certain imports strengthened local supply chains and encouraged domestic procurement. This scenario offered suppliers an opportunity to maintain firm pricing.
Logistics and transportation conditions in the region remained stable throughout the quarter, further supporting balanced supply dynamics. The demand from downstream sectors like personal care and fortified food products also contributed to this price trend. The overall Glucosamine market behaviour in first quarter of 2025 reflected cautious yet strategic procurement by buyers who aligned their purchases with seasonal demand patterns and policy adjustments.
Asia Pacific
The Asia Pacific Glucosamine market experienced a quarterly average price increase of 0.50% in first quarter of 2025. The price movement was steady, supported by moderate demand from pharmaceutical and nutraceutical industries across the region. A key factor influencing the market was the seasonal transition from winter to spring, which typically affects the consumption patterns of Glucosamine supplements and joint care products.
The Lunar Year holiday celebrations in February resulted in brief market closures in the APAC region and post-holiday demand recovery played a role in maintaining price stability. Glucosamine suppliers strategically managed inventories, avoiding oversupply situations while responding to consistent inquiries from buyers looking to replenish stocks ahead of the new production cycles. Demand from downstream sectors like wellness drinks and fortified functional foods remained steady but not aggressively high.
Smooth logistics operations and stable transportation costs also contributed to the balanced price trend during the quarter. Overall, the market showed a cautious but healthy pace in first quarter of 2025, with procurement aligning closely with seasonal shifts and supplier’s pricing strategies to avoid volatility.
Europe
In Europe, the Glucosamine prices followed a moderately stable trend during the first quarter of 2025 and mirrored the measured increases seen in other key markets. While the Glucosamine market varied from country to country, but the broader behaviour aligned closely with global trends, particularly those from export regions like North America and Asia Pacific.
Pharmaceutical and nutraceutical demand remained steady across major economies with Glucosamine supplements and wellness-focused products maintaining regular offtake. Seasonal transitions from colder months to early spring supported stable downstream consumption, especially in personal care and functional food products. Glucosamine suppliers in Europe managed inventories strategically and ensured market balance to avoid surplus situations.
Transportation and logistics networks performed smoothly throughout the first quarter and supported uninterrupted trade flows. Glucosamine buyers showed careful procurement behaviour and adjusted purchases based on anticipated production cycles and seasonal consumption needs. Overall, the European Glucosamine market displayed a calm and steady tone which was shaped by consistent demand and supplier strategies aligned with broader international market patterns.
For the Quarter Ending December 2024
North America
During Q4 2024, Glucosamine prices in North America, particularly in the USA, exhibited a steady downward trend of -1.06%, declining from $7,530 per MT in October to $7,450 per MT FOB New Jersey in December 2024. This consistent price decline stemmed from various factors. Despite initial support from pharmaceutical and nutraceutical industries' demand, prices continued to soften. US importers had built strategic stocks ahead of China's Golden Week holiday, which contributed to the bearish market sentiment. The post-holiday period saw continued price pressure as supply chains normalized, further accelerating the downward trend.
In Q4 2024, logistical challenges at Shanghai and Los Angeles ports, combined with labor disputes including the ILA strike affecting East and Gulf Coast operations, initially caused concern. However, these factors couldn't prevent the declining price trajectory. Market participants maintained routine procurement despite anticipated U.S. tariff changes, while Chinese exporters continued to offer competitive prices. December saw further price erosion as domestic suppliers implemented destocking initiatives while Chinese export prices softened, creating additional advantages for US buyers.
The market's downward momentum intensified as 2024 drew to a close. Despite the consistent price decline, underlying end-user demand remained stable throughout the quarter, particularly in pharmaceutical and nutraceutical applications. However, this steady consumption wasn't enough to offset the bearish market forces, resulting in continued price deterioration through the quarter's end.
APAC
In Q4 2024, Glucosamine prices in APAC demonstrated a persistent decline, falling from $5,605 per MT in October to $5,425 per MT FOB Shanghai in December. The quarter began with the Chinese Golden Week holiday, temporarily pausing market activities. Despite international buyers securing supplies through pre-emptive procurement, prices continued their downward trajectory. The post-holiday period saw further price erosion, even as market activity resumed. Lower freight rates and improved logistics costs weren't sufficient to prevent the continued price decline.
December witnessed further price depreciation as systematic destocking initiatives were implemented across the supply chain before the Christmas. Manufacturers and suppliers actively adjusted their inventory positions ahead of the holiday season, intensifying the downward pressure. While demand fundamentals remained relatively stable, with consistent procurement patterns across both domestic and international channels, prices continued to soften. This created increasingly attractive buying opportunities as the quarter progressed.
Europe
In Q4 2024, Glucosamine prices negotiations in Germany maintained a steady decline. Despite initial market stability supported by proactive stocking ahead of China's Golden Week and steady consumption from pharmaceutical and nutraceutical sectors, prices continued their downward trend throughout the quarter.
The bearish sentiment persisted through November, despite stable end-user demand. German buyers benefited from the declining price trend, while merchants faced pressure on profit margins due to the consistent price erosion in the market. December saw further price weakening as European distributors actively reduced inventory levels while Chinese exporters continued to lower their prices. This created increasingly favorable buying conditions, encouraging strategic purchases from Asian suppliers. While market fundamentals remained relatively healthy with steady consumption in both pharmaceutical and nutraceutical sectors, prices continued their downward trajectory through the quarter's end.
